Abstract
Behavioral and psychotic manifestations, including aggression, delusions, and hallucinations,
are frequent comorbidities in patients with debilitating nervous illnesses such as Alzheimer’s
disease (AD), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson’s disease. ADrelated
psychosis may be linked to a poor disease prognosis, highlighting that early detection and
management are mandatory. The manifestations are variable and may be very heterogeneous, imposing
a real diagnostic issue. Some assessment tools such as BEHAVE-AD, CERAD-BRSD, and the
Psycho-Sensory Hallucinations Scale have been designed to facilitate the diagnosis. The mechanisms
behind neurodegeneration-related psychosis are complex and are not fully understood, imposing a
burden on researchers to find appropriate management modalities. Familial history and some genetic
disturbances may have a determinant role in these delusions and hallucinations in cases with AD.
The loss of neuronal cells, atrophy in some regions of the central nervous, and synaptic dysfunction
may also contribute to these comorbidities. Furthermore, inflammatory disturbances triggered by
pro-inflammatory agents such as interleukins and tumor necrosis factors are stratified among the potential
risk factors for the onset of numerous psychotic symptoms in Alzheimer’s patients. Little is
known about the possible management tools; therefore, it is urgent to conduct well-designed trials to
investigate pharmacological and non-pharmacological interventions that can improve the care process
of these patients. This review summarizes the current findings regarding the AD-related psychosis
symptoms, pathological features, assessment, and management.
Keywords:
Alzheimer’s disease, psychosis, pathogenesis, assessment, management, dementia.
[38]
Review L. Delusions in Alzheimer’s Disease : A Literature Review. 2004; 11-5.
[56]
Rubin EH. Delusions as part of alzheimer’s disease. Neuropsychiatry Neuropsychol Behav Neurol 1992; 5(2): 108-13.
[90]
Lopez OL, Becker JT, Brenner RP, Rosen J, Bajulaiye OI, Reynolds CF. Alzheimer’s disease with delusions and hallucinations. Neurology 1991; 41(6): 906 LP.
[95]
Mulsantab Z-QEFAS H.. Neuroimaging of delusions in Alzheimer’s disease. 2012; 202(2): 89-95.
[99]
Ismail Z, Nguyen M, Mulsant BH, Mamo D. Neurobiology of delusions in alzheimer ’ s disease 2011; 211-8.
[100]
George S, Moossy John, Martinez M Julio, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. 1991.
[101]
Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM. Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer’s disease. Biochem Neuropathol Clin Correl neurofibrillary degenration Alzheimer’s Dis Springer Publ New York 1995; 57-80.
[102]
Lai MK P, Lai O –F, Keene J, Esiri MM, Francis PT, Hope T, et al. Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 2001; 57(5): 805LP-11.
[119]
Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. 2012.
[150]
Ballard C, Youakim JM, Coate SS B. Pimavanserin in alzheimer’s disease psychosis: Efficacy in patients with more pronounced psychotic symptoms. J Prev Alzheimer’s Dis - JPAD© 2019; 6(1)
[156]
Devanand DP, Crocco E, Forester BP, Husain MM, Lee S, Vahia I V, et al. Low Dose lithium treatment of behavioral complications in alzheimer’s disease: lit-ad randomized clinical trial. Am J Geriatr psychiatry Off J Am Assoc Geriatr Psychiatry 2022; 30(1): 32-4.
[160]
De Oliveira AM, Radanovic M, De Mello PCH, Buchain PC, Vizzotto ADB, Celestino DL, et al. Non-pharmacological interventions to reduce behavioral and psychological symptoms of dementia: A systematic review. BioMed Res Int 2015; 2015
[161]
Manuscript A, Syndromes GP. Five Things That Healthcare Providers and Patients Should Question 2010; 48(Suppl. 2): 1-6.